Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2025 06:35 ET | Source: Research and Markets

Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies

Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The "Hepatitis D Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnostic Method, and Region - Analysis and Forecast, 2025-2035" report...
September 04, 2025 07:54 ET | Source: Research and Markets

Trends & Strategies in the Thymalfasin Drugs Market 2025-2030: A Central Player in Value-Based Care and Personalized Medicine

Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Thymalfasin Drugs Market by Indication (Cancer, Hepatitis B, Hepatitis C), Route of Administration (Intramuscular Injection, Subcutaneous Injection),...
August 05, 2025 09:11 ET | Source: Research and Markets

Lassa Fever Market Analysis and Forecast Report 2025-2035 | Emerging Antivirals Target Lassa Fever with Promising Clinical Trials

Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Lassa Fever Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The...
September 21, 2023 06:59 ET | Source: Research and Markets

Rise in Viral Infections Drives Growth in the Oral Antiviral Market: 2021-2031 Forecast

Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com announces a comprehensive analysis of the Oral Antiviral Market, projecting a promising CAGR of 2.1% from 2022 to 2031. The "Oral...
September 30, 2019 09:38 ET | Source: Fior Markets

Global Antimicrobial Ingredients Market is Expected to Reach USD 10.72 Billion by 2025 : Fior Markets

New Jersey, NJ, Sept. 30, 2019 (GLOBE NEWSWIRE) -- The importance of antimicrobial ingredients in extending the shelf life of cosmetic products is a key factor driving the growth and adoption of...
September 09, 2014 03:00 ET | Source: OnCore Biopharma, Inc.

OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection

OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...